Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non–Small-Cell Lung Cancer
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.